Automated Cryopreparation of Apheresis Material using the Cue® Cell Processing System by Fresenius Kabi

Written by Fresenius Kabi
Cell therapy Industry developments

The manufacture of autologous cell and gene therapy products is not only a process development challenge, but a logistical one. Cryopreservation of the starting apheresis material can help provide a higher-quality and more standardized cellular product that is more stable for transport. This reduces risk in logistics-related delays and can help ensure the availability of manufacturing resources after receipt. 

In this application note, explore the use of the Cue Cell Processing System for the automated, closed system cryopreparation of fresh leukapheresis starting material for further manufacture.  

This content was supplied by Fresenius Kabi.

0101-CUE-01-0622_Cue White Paper

This article is part of the RegMedNet Spotlight on cryopreservation. Click here to view the full feature and discover expert insights on this >>>